Clinical trials sponsored by Boehringer Ingelheim

Phase breakdown

Conditions studied

Recruiting trials led by Boehringer Ingelheim

• A Study of BI 3810944 in Patients With Advanced Cancer
  NCT07224425 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
  NCT07107945 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 93 locations
• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
  NCT06636656 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 41 locations
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 55 locations
• A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  NCT07409181 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 140 locations
• A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
  NCT07754461 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 121 locations
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  NCT06935370 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 588 locations
• Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
  NCT07486817 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 105 locations
• Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)
  NCT05819385 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
  NCT05882058 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 59 locations
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 557 locations
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1147 locations
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
  NCT06632457 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 445 locations
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 530 locations

Common questions

How many trials is Boehringer Ingelheim recruiting for?

Boehringer Ingelheim is the lead sponsor of 15 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.